Board Meeting5 Aug 2026, 05:10 pm
Bliss GVS Pharma Board Meeting on Aug 12 to Approve Q1 FY27 Results
AI Summary
Bliss GVS Pharma Ltd has announced that its Board of Directors will convene on August 12, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. In line with SEBI regulations, the company has also closed its trading window for designated persons and their immediate relatives from July 01, 2026, until 48 hours after the financial results are announced. This information is available on the company's website.
Key Highlights
- Board meeting scheduled for August 12, 2026.
- To approve Unaudited Standalone and Consolidated Financial Results for Q1 FY27.
- Trading window closed from July 01, 2026, until 48 hours post-results.
- Disclosure made as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Price Impact
More from BLISSGVS